Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Sponsor:Global Coalition for Adaptive Research
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS2589
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called study drugs and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a newly diagnosed or recurrent glioblastoma?YesNo
Are you willing and able to provide written informed consent and to comply with the study protocol?YesNo
Submit
Cancel
Investigator
Andrew Lassman, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162